Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Emcyt
Estramustine is a nitrogen mustard alkylating agent linked to estradiol. It's used in the palliative treatment of metastatic and progressive prostate cancer. It's classified as an antineoplastic agent and specifically targets prostate cancer cells by binding to estrogen receptors and disrupting DNA replication. It also exhibits some estrogenic and anti-androgenic properties.
For the palliative treatment of metastatic and progressive prostate cancer.
Outcome:
Increased risk of bleeding
Mechanism:
Estramustine can inhibit the metabolism of warfarin.
Outcome:
Increased digoxin levels
Mechanism:
Potential interaction, monitor digoxin levels.
Outcome:
Decreased estramustine absorption
Mechanism:
May bind to estramustine in the GI tract.
Most likely new formulation: None anticipated in the near future (5 years, <5% confidence).
Based on current usage trends and ongoing clinical trials, there is a low (10%) likelihood of any major regulatory changes in the next 5 years.
Antineoplastic Agent, Alkylating Agent, Estrogen
Nitrogen Mustard Derivative